A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT ID: NCT00622258

Last Updated: 2020-12-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-03-31
• Study Completion Date: 2014-01-31

Brief Summary

This study assesses the tolerability, safety, efficacy and pharmacokinetics of everolimus in Japanese patients. Everolimus is administered orally everyday to adult patients with relapsed or refractory non-Hodgkin's lymphoma who have progressed despite standard therapy or for whom standard systemic therapy dose not exist.

Conditions

Non-Hodgkin's Lymphoma

Keywords

everolimus; mTOR inhibitor; non-Hodgkin's lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Everolimus

Group Type: EXPERIMENTAL

Everolmus

Intervention Type: DRUG

Interventions

Everolmus

Intervention Type: DRUG

Other Intervention Names

RAD001

Eligibility Criteria

Inclusion Criteria

• Patients must have histopathologically confirmed diagnosis of non-Hodgkin's lymphoma
• Patients must have disease that is either relapsed or refractory after at least one prior treatment regimen and must not be eligible for any standard treatments
• Patients must not have received autologous stem cell transplant at least within 12 weeks prior to study treatment. If patients received autologous stem cell transplant more than 12 weeks ago, they must be fully recovered from the side effects of such treatment
• Patients who have not received autologous stem cell transplant must be either ineligible for the treatment or, if eligible, patients must have chosen not to receive stem cell transplant
• Patients must have at least one measurable lesion
• Age above 20 years old
• Performance Status 0, 1, or 2 on Eastern Cooperative Oncology Group (ECOG) scale
• Patients with a life expectancy of at least 12 weeks
• Patients must be willing to provide portion of bone marrow aspirate and biopsy during study

Exclusion Criteria

• Patients with history of another primary malignancy that is currently clinically significant or currently requires active intervention
• Patients with prior allogeneic stem cell transplant
• Patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
• Patients who have received radiation therapy for ≤ 28 days prior to first study treatment or who have not recovered from side effects of such therapy.
• Patients who have received any other investigational agents ≤28 days prior to the first study treatment
• Patients who have received anti-neoplastic therapy within 28 days (60 days for monoclonal antibody or radioimmunotherapy) prior to the first study treatment or who have not recovered from side effects of such therapy
• Patients who have received treatment with oral or intravenous steroids or any immunosuppressive agents ≤ 28 days prior to the first study treatment
• Patients who have received prior therapy with RAD001 or other mTOR inhibitors
• Patient with prior therapy of > 450 U blomycin
• Patients with an active, bleeding diathesis.
• Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF) ≤ 14 days prior to the first study treatment
• Patients who have an impairment of gastrointestinal function or who have gastrointestinal disease that may significantly alter the absorption of study treatment (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
• Patients with active respiratory (excluding interstitial lung disease), skin, mucosal, renal, neurological, or ocular disorder of grade > 1
• Patients with a history of interstitial lung disease of grade ≥ 1
• Patients with a known history of human immunodeficiency virus seropositivity, hepatitis B or C seropositivity

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Novartis Investigative Site

Nagoya, Aichi-ken, Japan

Novartis Investigative Site

Nagoya, Aichi-ken, Japan

Novartis Investigative Site

Kashiwa, Chiba, Japan

Novartis Investigative Site

Isehara, Kanagawa, Japan

Novartis Investigative Site

Sendai, Miyagi, Japan

Novartis Investigative Site

Chuo-ku, Tokyo, Japan

Novartis Investigative Site

Fukuoka, , Japan

Novartis Investigative Site

Kyoto, , Japan

Countries

Japan

Related Links

https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13003

Results for CRAD001C1104 can be found on the Novartis Clinical Trial Results Website

Other Identifiers

CRAD001C1104

Identifier Type: -

Identifier Source: org_study_id